Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia.
Matthew I Balcerek, Brendan J Nolan, Adam Brownhill, Peggy Wong, Peter Locke, Jeffrey D Zajac, Ada S Cheung
Front Endocrinol (Lausanne) | Frontiers Media SA | Published : 2021
Context: The safety and efficacy of feminizing hormone therapy in aging transgender (trans) individuals is unclear. Current recommendations suggest transdermal estradiol beyond the age of 45 years, especially if cardiometabolic risk factors are present. Objective: To evaluate feminizing hormone therapy regimens and cardiovascular risk factors in aging trans individuals. Design: Retrospective cross-sectional analysis. Setting: Primary care and endocrine specialist clinic in Melbourne, Australia. Participants: Trans individuals on feminizing therapy for ≥6 months. Main Outcomes Measures: Feminizing hormone regimens and serum estradiol concentrations by age group: (a) ≥45 years, (b) <45 years, ..View full abstract
Related Projects (2)
Awarded by National Health and Medical Research Council